| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Burnett Patrick | Reporting Person's Title: Executive Vice President and Chief Medical Officer | C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE | /s/ Latha Vairavan, Attorney-in-Fact for Patrick Burnett | 2025-08-21 | 0001741987 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ARQT | Common Stock | Sale | -$28.3K | -1.75K | -1.61% | $16.16 | 107K | Aug 19, 2025 | Direct | F1, F2 |
| transaction | ARQT | Common Stock | Sale | -$38K | -2.44K | -2.27% | $15.57 | 105K | Aug 21, 2025 | Direct | F3, F4 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based Restricted Stock Units. |
| F2 | The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $15.87 to $16.73, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
| F3 | The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on December 12, 2024, by the Reporting Person, with a plan end date of February 27, 2026. |
| F4 | The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $15.43 to $15.65, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
Reporting Person's Title: Executive Vice President and Chief Medical Officer